Delving into the Latest Updates on Ascendis Pharma Endocrinology Division A/S with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1
神经系统疾病	1

排名前五的药物类型	数量

激素	1

排名前五的靶点	数量

GR(糖皮质激素受体)	1

关联

1

项与 Ascendis Pharma Endocrinology Division A/S 相关的药物

Lonapegsomatropin-tcgd

隆培促生长素

靶点

GR

作用机制

GR激动剂

在研机构

Ascendis Pharma A/S [+4]

原研机构

Ascendis Pharma A/S

在研适应症

生长激素缺乏症 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2021-08-25

9

项与 Ascendis Pharma Endocrinology Division A/S 相关的临床试验

EUCTR2021-004313-39-DE

/ Not yet recruiting临床3期

A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone Deficiency

开始日期2023-05-31

申办/合作机构

Ascendis Pharma Endocrinology Division A/S

NCT05820672

/ RecruitingN/A

A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

开始日期2023-03-20

申办/合作机构

Ascendis Pharma Endocrinology Division A/S

NCT05775523

/ RecruitingN/A

A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.

开始日期2023-03-20

申办/合作机构

Ascendis Pharma Endocrinology Division A/S

100 项与 Ascendis Pharma Endocrinology Division A/S 相关的临床结果

登录后查看更多信息

0 项与 Ascendis Pharma Endocrinology Division A/S 相关的专利（医药）

登录后查看更多信息

100 项与 Ascendis Pharma Endocrinology Division A/S 相关的药物交易

登录后查看更多信息

100 项与 Ascendis Pharma Endocrinology Division A/S 相关的转化医学

登录后查看更多信息